Background: Germline mutations in the BRCA1 and BRCA2 genes confer an estimated 58-80%
Introduction
In Mexico, breast cancer has overtaken cervical cancer as the leading cause of cancer-related death in women (1) (2) (3) (4) and mortality rates are increasing (5) (6) (7) . Typically, breast cancer is diagnosed at a relatively advanced stage (III and above) (8) (9) when the chance of cure is reduced. The median age of breast cancer diagnosis is 51 years (approximately one decade younger than that of women in Europe or North America) and almost one-half of Mexican women are premenopausal at breast cancer diagnosis (6) (7) (8) .
The BRCA1 (10) and BRCA2 (11) genes account for between 5% and 10% of all breast cancer cases, and particularly in those women with a family history of breast and ovarian cancer (12) (13) (14) (15) but the prevalence of mutations in these genes in Latin American women and their contribution to breast cancer is largely unknown. The lifetime risk of breast cancer in women who carry a BRCA1 or BRCA2 mutation is about 80% (12) (13) (14) but the absolute risk varies by country and by ethnic group (16) . Characteristics of hereditary breast cancer include a young at age at onset and multiple cases of early-onset breast cancer or ovarian cancer in the family (12) (13) (14) . However, as many as 50% of breast cancer patients with an inherited mutation in BRCA1 and BRCA2 do not have a close relative with breast or ovarian cancer, either because their mutation is paternallyinherited, their family is small, random segregation and incomplete penetrance (17) .
The prevalence of BRCA1 and BRCA2 mutations combined is approximately 0.3% in North America (12) (13) (14) (15) (16) (17) , but may be higher than this in countries or populations where there are founder mutations, such as Israeli Jews (18) (19) (20) , Dutch (21) , French-Canadians (22) , Icelandic (23) , Greenlandic (24) , Polish (25) , Russia and Eastern European (26) (27) (28) (29) (30) and Greek populations (31) (32) . Recurrent mutations have also been described in women of Hispanic origin in the United
States (33) (34) (35) (36) (37) (38) . The presence of recurrent BRCA1 and BRCA2 mutations has been noted in a few studies from Latin America and the Caribbean (39) (40) (41) (42) including four small studies from Mexico (43) (44) (45) (46) . The identification of recurrent mutations greatly facilitates genetic testing of BRCA1 and BRCA2 (47) . In this study, we screened for 26 mutations that have been observed previously in Mexican women and we have screened for other mutations in exon 11 in BRCA1 and exons 10 and 11 in BRCA2 in 810 Mexican women with breast cancer.
Materials and Methods

Materials
A multi-center breast cancer case-control study was established in twelve hospitals in three cities in Mexico (Mexico City, Monterrey and Veracruz). DNA and epidemiological data has been collected from January 2007 through June 2010 (48) (49) (50) (51) . Table 1 provides some of the descriptive statistics of 810 cases. A full summary of features of the cases and controls has been published elsewhere (48) (49) (50) (51) . The controls are not the focus of this current study. This study was designed to examine predictors of breast cancer risk among women age 35 to 69 years. Cases were histologically-confirmed new diagnosis of breast cancer, including invasive and in situ tumors. Data collection included the administration of a structured questionnaire by means of a face to face interview and anthropometric measurements and collection of a blood sample at the hospital by a trained nurse. All participants provided a written informed consent. The study was approved by the Institutional Review Board at each participating institution. The health questionnaire collected information on socio-demographic characteristics; reproductive factors; use of oral contraceptives and hormone replacement therapy; family and personal history of chronic diseases; personal history of transmitted sexual diseases; histories of body size, smoking, and alcohol consumption; and history of medical X-rays and mammograms. Subjects were informed of the goals of the study and the implications of the possible identification of a 
Laboratory Methods
Biospecimen Processing
Once a subject agreed to participate in the study, the research nurse collected blood samples in two five ml EDTA tubes. Blood samples were stored at each hospital at -20°C to -70°C and within three weeks they were sent to the Instituto Nacional de Salud Pública, Cuernavaca, Mexico and stored at -70°C until shipment. The frozen blood was shipped on dry ice to the Narod laboratory in Toronto. Genomic DNAs were extracted from blood using the ArchivePure DNA Blood Kit (5Prime, Gaithersburg, MD) according to protocol. Stock DNA samples were bar-coded with a unique subject identification number to ensure reliable sample processing. was used. The 185delAG mutation, commonly seen in the Hispanic women in the US of apparent Mexican and Jewish ancestry was coupled in a previously designed multiplex assay (52) . In addition, we tested for the BRCA1 5382insC and BRCA2 6174delT mutations commonly seen in Jews and others of eastern European ancestry using the same rapid multiplex method (52) . Mutation-positive controls were included in the assay. All primer designs and PCR conditions are available upon request. To compare characteristics by menopausal or mutation status, Kruskal Wallis for continuous variables and Chi Square and Fisher´s exact tests for categorical variables were used. The differences were considered statistically significant when p<0.05. All analyses were conducted using Stata v. 12.
Results
Eight hundred and ten women with breast cancer were included in the study. Of the 810 women, 66% were from Mexico City, 22% from Monterrey and 12% from Veracruz. The median age of diagnosis was 51.5 years and 334 (41% of total) were premenopausal. A family history of any cancer was reported in 34% of the postmenopausal women and in 23% of the premenopausal women (p = 0.001). However, the frequency of first degree relatives with breast cancer was similar in both groups (Table 1) .
Thirty-five mutations were identified in 34 of the 810 women (4.3%), (Table 2 ). In BRCA1, four recurrent mutations and four private mutations were detected in 20 women. The exon 9-12 mutation was detected in eight women. The exon 18 C5242A mutation was detected in four women and two mutations were seen twice (exon 11 2552delC and exon 13 C4446T). In BRCA2, two recurrent mutations and nine private mutations were detected in 14 women. Two BRCA2 mutations were seen three times each (exon 10 2024del5 and exon 11 C4339T). One woman harbored two BRCA2 mutations (exon 10 2024del5 and 4321insAA). No Jewish founder mutations (BRCA1 exon 2 185delAG and exon 11 5382insC and BRCA2 exon 11 6174delT) were detected. Eighteen of the women (53%) with a BRCA mutation were from Mexico City; eight mutation-carriers (23%) were from Monterrey and eight mutation-carriers (23%) with nine mutations were from Veracruz (including the woman with two BRCA2 mutations). The BRCA2 exon 11 2024del5 mutation was only found in three women from Veracruz ( Table 2 ).
The mean age of breast cancer onset was 43 years in BRCA1 carriers; 50.9 years in BRCA2 carriers and was 52 years in non-carriers (p<0.001) ( Table 3 ). The prevalence of mutations was 11.8% for women diagnosed aged 30-39; 4.8% for women diagnosed aged 40-49; 3.4% for women diagnosed aged 50-59 and 1.6% for women diagnosed at 60 years or older.
A history of any cancer in a first degree relative was reported in 55% of BRCA1 carriers, 46.7% of BRCA2 carriers and 28.5% of non-carriers. However, breast cancer in a first-degree relative was seen in only three of 20 (15%) women with BRCA1 mutations and two of 15 (13.3%) women with a BRCA2 mutation and 53 of 775 (6.8%) of non-carriers. The prevalence of mutations by cancer family history is provided in Table 3 .
European ancestry was not associated with either BRCA1 or BRCA2 carrier status (Table 3 ).(51)
Discussion
We conducted a breast cancer case-control collection in 12 hospitals in three cities in Mexico.
Eight hundred and ten blood samples from women with breast cancer were collected of whom 334 (41%) were premenopausal and 476 (59%) were postmenopausal. Thirty-five mutations were identified in 34 of the 810 (4.3%) women tested including 8 unique BRCA1 mutations in 20 women and 11 unique BRCA2 mutations in 14 women (Table 2) . Genetic testing for mutations in BRCA1 and BRCA2 has potentially important public health implications for the detection of high risk individuals for whom targeted prevention and tailored management strategies can be implemented (53) . The ability to offer genetic testing in Mexico on a widespread level would be enhanced with the identification of common mutations in the two genes so the cost of genetic sequencing is reduced. In the present study, we detected recurrent mutations in 2.7% of 810 unselected cases of breast cancer. Twenty-two of the 34 mutation carriers had a mutation that was seen more than once, therefore the strategy of looking solely for recurrent mutations would have a sensitivity of approximately 60%. Ideally, to maximize sensitivity, one would screen all breast cancer patients for both BRCA1 and BRCA2 in their entirety. However, given the current high costs of sequencing, this strategy is prohibitively expensive in Mexico. Alternate strategies include the testing of all high-risk patients for all mutations through full gene sequencing or testing all cancer patients (high and low-risk) for a smaller number of mutations (recurrent and founder mutations). Of interest, in the present study, only three of 20 (15%) women with BRCA1 mutations (all with the exon 9-12 deletion) and two of 14 (14.3%) women with a BRCA2 mutation (one harboring a 3036delACAA and another with 5770delA mutation) had a first degree relative with breast cancer (Table 3 ) and therefore the strategy of testing only familial cases of breast cancer would result in the identification of only a minority of mutation carriers, even if complete sequencing were done for both genes. The three women with the BRCA1 exon 9-12 deletion developed breast cancer at 44, 44 and 56 years respectively. The two women with BRCA2 mutations were <50 years at diagnosis (one was 42 years and the other woman was 48 years).
There are small reports of BRCA1/2 mutation screening studies in Mexico. Ruiz-Flores et al, (43) , identified one BRCA1 3857delT and one BRCA2 2663-2664insA mutation among in 51 
Mexican breast cancer patients, (6% of 32 early-onset breast cancer patients). Vidal-Millan et al, (44) Mexican women. However, we did not detect any of the above mutations.
Of note, no Jewish founder mutations were reported in any of these four studies, nor did we detect women harboring these mutations in this study. However, mutation screening studies performed in Latina women, mainly of Mexican origin in the United States revealed the presence of the Jewish BRCA1 exon 2, 185delAG founder mutation. Vogel et al reported that four of 78 Hispanic women with familial breast cancer carried this mutation and ten carried other mutations including BRCA1 2552delC (37). John et al, found a BRCA1 mutation in 21 of 393 (5.3%) of Hispanic women with breast cancer in California (38) . They found the prevalence of BRCA1 mutation carriers of 3.5% (95% CI, 2.1%-5.8%) in Hispanic patients (n = 393), compared with 8.3% (95% CI, 3.1%-20.1%) in Ashkenazi Jewish patients (n = 41) and 2.2% (95% CI, 0.7%-6.9%) in other non-Hispanic white patients (n = 508). The BRCA1 185delAG was the most common mutation in Hispanics and was found in five of 21 carriers (24%). Weitzel and colleagues (33) studied 110 unrelated Latina women at high risk of breast/ovarian cancer in Los Angeles. Thirty-four of the 110 women had a mutation (31%); of these 18 were of Mexican descent. Four mutations were seen more than once in women with Mexican origins: BRCA1 exon 2 185delAG (four times); exon 13 C4446T (R1443X) (three times); exon 11 2552delC (2 times) and BRCA2 exon 11 3492insT (2 times). In a more recent follow-up study (34) , the BRCA1 exon 13 C4446T (R1443X) was reported six times, four of which were in families of Mexican descent. The 2552delC was reported in four families and the A1708E was observed in three families of Mexican origin. The latter was also reported by Myriad Genetics in seven Latin American subjects in the BIC database (54) . The BRCA2 exon 11 3492insT was identified in 10 families of Mexican descent only. In this study, we also identified the BRCA1 exon 13 C4446T (R1443X) twice; the exon 11 2552delC twice, the A1708E four times and BRCA2 exon 11 3492insT once. Weitzel et al (33) also reported single BRCA1 mutations which we also detected in the current study, each in a single individual: 1135insA, 2415delAG and C3717T (Q1200X).
We found recurrent BRCA2 mutations; exon 10 2024del5, (which was reported 11 times in BIC (54) but not in individuals of Latin American descent) and exon 11 C4339T (reported once in BIC (54) in an individual of Spanish descent) in three cases each. We identified a BRCA2 3036del4 mutation in a single case which was also identified by Osario et al, (55) in a Spanish breast cancer family, while the 2024del5 mutations appears to be of Greek origin (31) (32) . In summary, the BRCA1 1135insA, 2415delAG, 2552delC, C3717T, C4446T, C5242A and 9-12del and BRCA2 2024del5, 3492insT and C4339T mutations are recurrent mutations in the Mexican population. One novel BRCA1 mutation (2190delA) and five novel BRCA2 mutations (2971del5, 4321insAA, 4534delAT, 5859delC and 6686delC) were also identified in our study, which were not previously reported.
However, we did not find any BRCA1 exon 2 185delAG mutations in agreement with the four previous reports in Mexican breast cancer patients (43) (44) (45) (46) (35) . We detected this mutation in eight women (1% of the 810 women tested) or 22% of all observed BRCA1/2 mutations.
Overall, the age of breast cancer onset was around 8 years younger in BRCA1 carriers (43 years) compared to BRCA2 carriers (50.9 years) and nine years younger than non-carriers (52 years) (p<0.001) ( Table 3) .
One woman with breast cancer at age 53 years harbored two BRCA2 mutations (exon 10 2024del5 and exon 11 4321insAA). The exon 10 2024del5 mutation is a common mutation in Greek breast cancer families (31) and was found only in three women from Veracruz in this 
study. Biallelic BRCA2 mutations have been reported in Fanconi anaemia (FA), specifically subtype D1 (59) . FA is a recessive condition associated with progressive bone marrow aplasia, congenital abnormalities and predisposition to leukaemia and solid tumours of the head and neck, oesophagus and vulva (60) . The biallelic BRCA2 mutations form of FA is severe with high risks of childhood cancer, particularly Wilms tumour, brain tumours and acute myelogenous leukaemia (59) (60) (61) . Recently, a woman with ovarian cancer was found to harbor biallelic BRCA1 mutations (62). To our knowledge, this is the first report of breast cancer in a biallelic BRCA2 mutation carrier. The combinations of BRCA2 mutations that are viable are limited. The exon 11 4321insAA has not been reported previously in BIC (54) or the literature and the functional impact of this mutation is unknown. Of note the Mexican woman with bialleleic BRCA2 mutations in this study did not show signs of FA so the 4321insAA mutation may be nondeleterious.
Medullary breast cancer has been highly associated with BRCA1 mutations (63) . In this study we found that 2/7 (28.5%) of the medullary breast cancers were from women with BRCA1 mutations. Although medullary breast cancer histologic subtypes represent a small number of the total number of breast cancers, the presence of this subtype is potentially an indicator for the presence of a BRCA1 mutation in Mexican women.
There are several strengths to this study. This is the largest study of BRCA1/2 mutations in Furthermore, there is the possibility that some of the women in the study are related which may inflate the frequency of particular mutations.
Another limitation is the inability to consider second-degree family relatives and that the presence of ovarian cancer was not adequately recorded. However, family history in seconddegree relatives is considered less predictive of BRCA-carrier status. Indeed, our results suggest that family history of breast cancer in first-degree relatives is not particularly predictive of BRCA-carrier status in Mexican women either.
In conclusion, studies of this kind are essential to determine the genetic etiology of breast cancer in Mexican women. These results highlight the variability in the mutation spectrum, penetrance and phenotype of BRCA1 and BRCA2 mutations in Mexican women and reveal the presence of particular recurrent mutations in this population. Further comprehensive evaluation of the prevalence of BRCA1 and BRCA2 mutations is necessary. Through judicious testing of women believed to be at high risk for early-onset breast cancer, it is possible to identify highly- preventive mastectomy or tamoxifen may be tailored to the BRCA1/2 mutation carrier so as to improve morbidity and mortality associated with this disease. We considered parents and siblings as first degree relatives. Participants who did not know their number of siblings were excluded from the analysis. We considered parents and siblings as first degree relatives. d Participants who did not know their number of siblings were excluded from the analysis.
